LakeShore Biopharma Co., Ltd

LakeShore Biopharma Co., Ltd is a biopharmaceutical company that discovers, develops, manufactures, commercializes, and sells vaccines and therapeutic biologics for infectious diseases and cancer. Its pipeline includes YSJA, a conventional rabies vaccine that is already marketed; PIKA, a rabies vaccine in Phase I/III and preclinical trials; PIKA YS-ON-001, an immuno-oncology candidate in Phase I for pancreatic and hepatocellular cancer; PIKA YS-HBV-001, a hepatitis B vaccine in Phase I; PIKA YS-HBV-002, an immune-therapy vaccine in preclinical trials for chronic HBV infection; and PIKA YS-ON-001 and PIKA Influenza Vaccine, both in preclinical trials. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. Founded in 1994, it is based in Beijing, China.